CC3 COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY: A FRENCH HEALTHCARE SYSTEM PERSPECTIVE

System Perspective ◽

Healthcare System Perspective ◽

Effectiveness Analysis ◽

Inherited Retinal Dystrophy

Cost Effectiveness Analysis of Sorafenib Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma from Health Care System Perspective in Egypt

Value in Health ◽

10.1016/j.jval.2017.08.235 ◽

2017 ◽

Vol 20 (9) ◽

pp. A439

Author(s):

Elkony ◽

GH Elsisi

Keyword(s):

Hepatocellular Carcinoma ◽

Health Care ◽

Cost Effectiveness ◽

Supportive Care ◽

Health Care System ◽

Best Supportive Care ◽

Advanced Hepatocellular Carcinoma ◽

System Perspective ◽

PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Value in Health ◽

10.1016/j.jval.2019.09.2368 ◽

2019 ◽

Vol 22 ◽

pp. S847

Author(s):

P. Souza ◽

G.R. Puopolo ◽

R. Leme-Souza

Keyword(s):

Cost Effectiveness ◽

Healthcare System ◽

Hemophilia A ◽

Public Healthcare ◽

System Perspective ◽

Healthcare System Perspective ◽

Public Healthcare System ◽

Effectiveness Analysis ◽

Bypassing Agents

Cost Effectiveness Analysis of Pirfenidone For The Treatment of Mild To Moderate Idiopathic Pulmonary Fibrosis (IPF) Compared To Best Supportive Care And Nintedanib From The Italian NHS Perspective

Value in Health ◽

10.1016/j.jval.2016.09.1211 ◽

2016 ◽

Vol 19 (7) ◽

pp. A556 ◽

Cited By ~ 2

Author(s):

R Ravasio ◽

M Ferrario ◽

M Pata ◽

P Thuresson

Keyword(s):

Cost Effectiveness ◽

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Supportive Care ◽

Best Supportive Care ◽

OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales

The European Journal of Health Economics ◽

10.1007/s10198-015-0737-2 ◽

2015 ◽

Vol 17 (7) ◽

pp. 911-921 ◽

Cited By ~ 6

Author(s):

Nick Freemantle ◽

Kristin Khalaf ◽

Clara Loveman ◽

Sanja Stanisic ◽

Dmitry Gultyaev ◽

...

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Supportive Care ◽

Best Supportive Care ◽

England And Wales ◽

Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis

The Lancet Global Health ◽

10.1016/s2214-109x(21)00261-8 ◽

2021 ◽

Author(s):

Matthew S Painschab ◽

Racquel Kohler ◽

Stephen Kimani ◽

Wilberforce Mhango ◽

Bongani Kaimila ◽

...

Keyword(s):

Cost Effectiveness ◽

Supportive Care ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Best Supportive Care ◽

Large B Cell Lymphoma ◽

Effectiveness Analysis ◽

Large B Cell

PCN68 COST-EFFECTIVENESS ANALYSIS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE (BSC) IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): THE PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL

Value in Health ◽

10.1016/s1098-3015(10)72157-4 ◽

2010 ◽

Vol 13 (3) ◽

pp. A36

Author(s):

N Muszbeck ◽

H Vioix ◽

U Munir ◽

A Schiola ◽

A Valderrama ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Health Care ◽

Cost Effectiveness ◽

Supportive Care ◽

Health Care System ◽

Best Supportive Care ◽

Advanced Hepatocellular Carcinoma ◽

Private Health Care ◽

System Perspective ◽

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

British Journal of Cancer ◽

10.1038/sj.bjc.6603561 ◽

2007 ◽

Vol 96 (2) ◽

pp. 206-212 ◽

Cited By ~ 62

Author(s):

N Starling ◽

D Tilden ◽

J White ◽

D Cunningham

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Supportive Care ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Best Supportive Care ◽

Chemotherapy Treatment ◽

Effectiveness Analysis ◽

Colorectal Cancer Patients

Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2016.17.2.799 ◽

2016 ◽

Vol 17 (2) ◽

pp. 799-805

Author(s):

Phanida Luealon ◽

Nipon Khempech ◽

Apichai Vasuratna ◽

Piya Hanvoravongchai ◽

Piyalamporn Havanond

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Supportive Care ◽

Management Strategies ◽

Best Supportive Care ◽

Second Line ◽

Second Line Chemotherapy ◽

Effectiveness Analysis ◽

Line Chemotherapy

A Cost-Effectiveness Analysis Of Onabotulinumtoxina Verse. Best Supportive Care (bsc) For The Treatment Of Anticholinergic Treatment-Refractory Neurogenic Detrusor Overactivity (ndo)

Value in Health ◽

10.1016/j.jval.2014.08.1329 ◽

2014 ◽

Vol 17 (7) ◽

pp. A470

Author(s):

R. Hamid ◽

C. Loveman ◽

J. Millen ◽

D. Colayco ◽

S. Stanisic ◽

...

Keyword(s):

Cost Effectiveness ◽

Supportive Care ◽

Detrusor Overactivity ◽

Best Supportive Care ◽

Neurogenic Detrusor Overactivity ◽

Effectiveness Analysis ◽

Treatment Refractory

Cost-Effectiveness Analysis of Sorafenib versus Best Supportive Care in Advanced Renal Cell Carcinoma in Spain

SSRN Electronic Journal ◽

10.2139/ssrn.944301 ◽

2006 ◽

Author(s):

Pablo Maroto ◽

Humberto Villavicencio ◽

Carme Pinol ◽

Leyre Urruticoechea

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Supportive Care ◽

Cell Carcinoma ◽

Renal Cell ◽

Best Supportive Care ◽

Advanced Renal Cell Carcinoma ◽